CLINICAL_TRIALS
trial_result
· 2015-10-29
Clinical Trial Update: Evaluation of the Diagnostic Utility of INS316 in Patients With Interstitial Lung Diseases (01-701) [Phase 2]
Summary
A Phase 2 diagnostic trial evaluating INS316 for interstitial lung diseases has been terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Merck Sharp & Dohme LLC | Conditions: Interstitial Lung Disease | Phase 2 | Status: TERMINATED